Abstract
Although the endocrine component of the pancreas represents about less than 10% of the volume of the gland, it plays a crucial role in regulating the metabolic functions, mainly the glucose metabolism. The diseases affecting the endocrine pancreas lead to clinical pictures due to the increase or decrease of glucose blood levels. Pathology of the endocrine pancreas includes non-neoplastic and neoplastic diseases. Among the former, diabetes mellitus and persistent hyperinsulinemic hypoglycemia in infancy (PHHI) and adults (PHHA) are two pathologies due, respectively, to the increase or decrease of glucose blood level. Diabetes mellitus represents one of the most important metabolic pathology with increasing relevant social implications in industrialized countries, while persistent hyperinsulinemic hypoglycemia, although rather rare, can be difficult to diagnose and has important therapeutic implications, especially for children. Pancreatic endocrine tumors are a heterogeneous group of neoplasms showing different morphological, molecular, and clinical aspects. Although less frequent than tumors originating in the exocrine pancreas, their incidence is increasing due to modern and more sensitive imaging investigations. Conversely, due to exocrine cancers, surgical and medical therapies play an important therapeutic role with favorable influence on patients’ survival in the majority of cases. In the present chapter, we describe the main clinicopathological features of both non-neoplastic and neoplastic diseases affecting the endocrine pancreas. In addition, we make an update of the most relevant molecular aspects, which are involved in the pathogenesis of such diseases.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Von Mering I, Minkowsky M (1889) Diabetes mellitus nach Pankreasextirpation. Zentral Klin Medizin 10:393–394
Laguesse E (1894) Sur la formation des ilots de Langerhans dans le pancréas. Comptes Rendus des Seances de la Sociéte de Biologie et de Ses Filiales Paris 46:819–820
Langerhans P (1869) Beiträge zur mikroskopischen anatomie der bauchspeicheldrüse. Berlin Univ, Berlin
Diamare V (1989) Studi comparativi sulle isole del Langerhans del pancreas. Int Monat Anat Physiol 16:155–209
Lane MA (1907) The cytological characteristics of the areas of Langerhans. Am J Anat 7:409–421
Bensley RR (1911) Studies on the pancreas of the guinea pig. Am J Anat 12:297–388
Bloom W (1931) A new type of granular cell in the islet of Langerhans of man. Anat Rec 49:363–371
Deconinck JF, van Assche FA, Potvliege PR, Gepts W (1972) The ultrastructure of the human pancreatic islets II. The islets of neonates. Diabetologia 8:326–333
Lacy PE, Davies J (1959) Demonstration of insulin in mammalian pancreas by fluorescent antibody method. Stain Technol 34:85–89
Okada N, Takaki R, Kitagawa M (1967) Histological and immunofluorescence studies on the site of origin of glucagon in mammalian pancreas. J Histochem Cytochem 16:405–409
Orci L, Baetens D, Dubois MP, Rufener C (1975) Evidence for D-cell of the pancreas secreting somatostatin. Horm Metab Res 7:400–402
Larsson LI, Sundler R, Håkanson R (1976) Pancreatic polypeptide. A postulated new hormone: identification of its cellular storage site by light and electron microscopic immunocytochemistry. Diabetologia 12:211–226
Fiocca R, Sessa F, Tenti P, Usellini L, Capella C, O’Hare MM, Solcia E (1983) Pancreatic polypeptide (PP) cells in the PP-rich lobe of the human pancreas are identified ultrastructurally and immunocytochemically as F cells. Histochemistry 77:511–523
Liu HM, Potter EL (1962) Development of the human pancreas. Arch Pathol 74:439–452
Edlund H (2001) Developmental biology of the pancreas. Diabetes 50(Suppl 1):S5–S9
Upchurch BH, Aponte GW, Leiter AB (1994) Expression of peptide YY in all four islet cell types in the developing mouse pancreas suggests a common peptide YY-producing progenitor. Development 120:245–252
Brand SJ, Fuller PJ (1988) Differential gastrin gene expression in rat gastrointestinal tract and pancreas during neonatal development. J Biol Chem 263:5341–5347
Wheeler MB, Nishitani J, Buchan AMJ, Kopin AS, Chey WY, Chang TM, Leiter AB (1992) Identification of a transcriptional enhancer important for enteroendocrine and pancreatic islet cell-specific expression of the secretin gene. Mol Cell Biol 12:3531–3539
Conklin JL (1962) Cytogenesis of the human fetal pancreas. Am J Anat 111:181–193
Lackie PM, Zuber C, Roth J (1994) Polysialic acid of neural cell adhesion molecule (N-CAM) is widely expressed during organogenesis in mesodermal and endodermal derivates. Differentiation 57:119–131
Dahl U, Sjodin A, Semb H (1996) Cadherins regulate aggregation of pancreatic beta-cells in vivo. Development 122:1895–2902
Jensen J (2004) Gene regulatory factors in pancreatic development. Dev Dyn 229:176–200
Bonal C, Herrera PL (2008) Genes controlling pancreas ontogeny. Int J Dev Biol 52:823–835
Kume S (2005) The molecular basis and prospects in pancreatic development. Dev Growth Differ 47:367–374
Gu G, Dubauskaite J, Melton DA (2002) Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 129:2447–2457
Ashizawa S, Brunicardi FC, Wang XP (2004) PDX-1 and the pancreas. Pancreas 28:109–120
Jonsson J, Carlsson L, Edlund T, Edlund H (1994) Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 371:606–609
Stanger BZ, Tanaka AJ, Melton DA (2007) Organ size is limited by the number of embryonic progenitor cells in the pancreas but not the liver. Nature 445:886–891
Apelqvist A, Li H, Sommer L, Beatus P, Anderson DJ, Honjo T, Hrabe de Angelis M, Lendahl U, Edlund H (1999) Notch signalling controls pancreatic cell differentiation. Nature 400:877–881
Hebrok M, Kim SK, Melton DA (1998) Notochord repression of endodermal Sonic hedgehog permits pancreas development. Genes Dev 12:1705–1713
Kumar M, Jordan N, Melton D, Grapin-Botton A (2003) Signals from lateral plate mesoderm instruct endoderm toward a pancreatic fate. Dev Biol 259:109–122
Li H, Arber S, Jessell TM, Edlund H (1999) Selective agenesis of the dorsal pancreas in kice lacking homeobox gene Hlxb9. Nat Genet 23:67–70
Harrison KA, Thaler J, Pfaff SL, Gu H, Kehrl JH (1999) Pancreas dorsal lobe agenesis and abnormal islets of Langerhans in Hlxb9-deficient mice. Nat Genet 23:71–75
Ahlgren U, Pfaff SL, Jessel TM, Edlund T, Edlund H (1997) Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. Nature 385:257–260
Gradwohl G, Dierich A, LeMeur M, Guillemot F (2000) Neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas. Proc Natl Acad Sci USA 97:1607–1611
Vinik AJ, Pittenger GL, Pavlic-Renar I (1993) Role of growth factors in pancreatic endocrine cells. Growth and differentiation. Endocrinol Metab Clin North Am 22:875–887
Peters J, Jürgensen A, Klöppel G (2000) Ontogeny, differentiation and growth of the endocrine pancreas. Virchows Arch 436:527–538
Finch P, Cunha G, Rubin JS, Wong J, Ron D (1995) Pattern of keratinocyte growth factor and keratinocyte growth factor receptor expression during mouse foetal development suggests a role in mediating morphogenetic mesenchymal-epithelial interactions. Dev Dyn 203:223–240
Orr-Urtreger A, Bedford MT, Burakova T, Arman E, Zimmer Y, Yayon A, Givol D, Lonai P (1993) Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol 158:475–486
Le Bras S, Miralles F, Basmaciogullari A, Czernichow P, Scharfmann R (1998) Fibroblast growth factor 2 promotes pancreatic epithelial cell proliferation via functional fibroblast growth factor receptors during embryonic life. Diabetes 47:1236–1242
Le Bras S, Czernichow P, Scharfmann R (1998) A search for tyrosine kinase receptors expressed in the rat embryonic pancreas. Diabetologia 41:1474–1481
Murtaugh LC (2007) Pancreas and beta-cell development: from the actual to the possible. Development 134:427–438
Scharfmann R (2000) Control of early development of the pancreas in rodents and humans: implications of signals from the mesenchyme. Diabetologia 43:1083–1092
Gonzales AM, Buscaglia M, Ong M, Baird A (1990) Distribution of basic fibroblast growth factor in 18-day rat fetus: localization in the basement membranes of diverse tissues. J Cell Biol 110:753–765
Gonzales AM, Hill DJ, Logan A, Maher PA, Baird A (1996) Distribution of fibroblast growth factor (FGF)-2 and FGF receptor-1 messenger RNA expression and protein presence in the mid-trimester human fetus. Pediatr Res 39:375–385
Mason I, Fuller-Pace F, Smith R, Dickson C (1994) FGF-7 (keratinocyte growth factor) expression during mouse development suggests roles in myogenesis, forebrain regionalisation and epithelial-mesenchymal interactions. Mech Dev 45:15–30
Scharfmann R, Czernichow P (2001) Soluble factors important for pancreatic development. In: Habener JF, Hussain MA (eds) Molecular basis of pancreas development and function. Kluwer, Norwell, pp 165–175
Nguyen HQ, Danilenko DM, Bucay N, DeRose ML, Van GY, Thomason A, Simonet WS (1996) Expression of keratinocyte growth factor in embryonic liver of transgenic mice causes changes in epithelial growth and differentiation resulting in polycystic kidneys and other organ malformations. Oncogene 12:2109–2119
Celli G, LaRochelle W, Mackem S, Sharp R, Merlino G (1998) Soluble dominant-negative receptor uncovers essential role for fibroblast growth factors in multi-organ induction and pattering. EMBO J 17:1642–1655
Ishiwata T, Friess H, Büchler MW, Sharp R, Merlino G (1998) Characterization of keratinocyte growth factor and receptor expression in human pancreatic cancer. Am J Pathol 153:213–222
La Rosa S, Uccella S, Erba S, Capella C, Sessa F (2001) Immunohistochemical detection of fibroblast growth factor receptors in normal endocrine cells and related tumors of the digestive system. Appl Immunohistochem Mol Morphol 9:319–328
Rane SG, Lee JH, Lin HM (2006) Transforming growth factor-beta pathway: role in pancreas development and pancreatic disease. Cytokine Growth Factor Rev 17:107–119
Ying SY (1988) Inhibins, activins and follistatin: gonadal proteins modulating the secretion of follicle-stimulating hormone. Endocr Rev 9:267–293
Kim S, Hebrok M, Melton D (1997) Notochord to endoderm signaling is required for pancreas development. Development 124:4243–4252
Mashima H, Shibata H, Mine T, Kojima I (1996) Formation of insulin-producing cells from pancreatic acinar AR42J cells by hepatocyte growth factor. Endocrinology 137:3969–3976
Mashima H, Yamada S, Tajima T, Seno M, Yamada H, Takeda J, Kojima I (1999) Genes expressed during the differentiation of pancreatic AR42J cells into insulin-secreting cells. Diabetes 48:304–309
Furkawa M, Eto Y, Kojima I (1995) Expression of immunoreactive activin A in fetal rat pancreas. Endocr J 42:63–68
Ogawa K, Abe K, Kurosawa N, Kurohmaru M, Sugino H, Takahashi M, Hayashi Y (1993) Expression of α βA and βB subunits of inhibin or activin and follistatin in rat pancreatic islets. FEBS Lett 319:217–220
Yasuda H, Inoue K, Shibata H, Takeuchi T, Eto Y, Hasegawa Y, Sekine N, Totsuka Y, Mine T, Ogata E, Kojima I (1993) Existence of activin A in A- and D-cells of rat pancreatic islet. Endocrinology 133:624–630
Wada M, Shintani Y, Kosaka M, Sano T, Hizawa K, Saito S (1996) Immunohistochemical localization of activin A and follistatin in human tissues. Endocr J 43:375–385
La Rosa S, Uccella S, Billo P, Facco C, Sessa F, Capella C (1999) Immunohistochemical localization of α- and βA-subunits of inhibin/activin in human normal endocrine cells and related tumors of the digestive system. Virchows Arch 434:29–36
La Rosa S, Uccella S, Marchet S, Capella C, Lloyd RV (2004) Localization of inhibins and activins in normal endocrine cells and endocrine tumors of the gut and pancreas: an immunohistochemical and in situ hybridization study. J Histochem Cytochem 52:217–225
Totsuka Y, Tabuchi M, Kojima I, Shibai H, Ogata E (1988) A novel action of activin A: stimulation of insulin secretion in rat pancreatic islets. Biochem Biophys Res Commun 156:335–339
Yamaoka T, Idehara C, Yano M, Matsushita T, Yamada T, Ii S, Moritani M, Hata J, Sugino H, Noji S, Itakura M (1998) Hypoplasia of pancreatic islets in transgenic mice expressing activin receptor mutants. J Clin Invest 102:294–301
Shiozaki S, Tajima T, Zhang YQ, Furukawa M, Nakazato Y, Kojima I (1999) Impaired differentiation of endocrine and exocrine cells of the pancreas in transgenic mouse expressing the truncated type II activin receptor. Biochim Biophys Acta 1450:1–11
Miralles F, Czernichow P, Scharfmann R (1998) Follistatin regulates the relative proportions of endocrine versus exocrine tissue during pancreatic development. Development 125:1017–1024
Ogawa K, Ono K, Kurohmaru M, Hayashi Y (1995) Effect of streptozocin injection on expression of immunoreactive follistatin and βA and βB subunits of inhibin/activin in rat pancreatic islets. Eur J Endocrinol 132:363–369
Miralles F, Battelino T, Czernichow P, Scharfmann R (1998) TGF-beta plays a role in morphogenesis of the pancreatic islets of Langerhans by controlling the activity of the matrix metalloproteinase MMP-2. J Cell Biol 143:827–836
Sanvito F, Herrera P, Huarte J, Nichols A, Montesano R, Orci L, Vassalli JD (1994) TGF-β1 influences the relative development of the exocrine and endocrine pancreas in vitro. Development 120:3451–3462
Yamanaka Y, Friess H, Büchler M, Beger HG, Gold LI, Korc M (1993) Synthesis and expression of transforming growth factor β-1, β-2, and β-3 in the endocrine and exocrine pancreas. Diabetes 42:746–756
Wang T, Bonner-Weir S, Oates P, Chulak M, Simon B, Merlino GT, Schmidt EV, Brand SJ (1993) Pancreatic gastrin stimulates islet differentiation of transforming growth factor alpha-induced ductular precursor cells. J Clin Invest 92:1349–1356
Wang RN, Rehfeld JF, Nielsen FC, Klöppel G (1997) Expression of gastrin and transforming growth factor-alpha during duct to islet cell differentiation in the pancreas of duct-ligated adult rats. Diabetologia 40:887–893
Miettinen P, Ormio P, Hakonen E, Banerjee M, Otonkoski T (2008) EGF receptor in pancreatic beta-cell mass regulation. Biochem Soc Trans 36:280–285
Kanaka-Gantenbein C, Dicou E, Czernichow P, Scharfmann R (1995) Presence of nerve growth factor and its receptors in an in vitro model of islet cell development: implication in normal islet morphogenesis. Endocrinology 136:3154–3162
Rooman I, Schuit F, Bouwens L (1997) Effect of vascular endothelial growth factor on growth and differentiation of pancreatic duct epithelium. Lab Invest 76:225–232
Öberg C, Waltenberg J, Claesson-Welsh L, Welsh M (1994) Expression of protein tyrosine kinases in islet cells: possible role of the Flk-1 receptor for β-cell maturation from duct cells. Growth Factors 10:115–126
Christofori G, Naik P, Hanahan D (1995) Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets throughout islet cell tumorigenesis. Mol Endocrinol 9:1760–1770
Kuroda M, Oka T, Oka Y, Yamochi T, Ohtsubo K, Mori S, Watanabe T, Machinami R, Ohnishi S (1995) Colocalization of vascular endothelial growth factor (vascular permeability factor) and insulin in pancreatic islet cells. J Clin Endocrinol Metab 80:3196–3200
La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, Capella C (2003) Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 34:18–27
Malaisse-Lagae F, Stefan Y, Cox J, Perrelet A, Orci L (1979) Identification of a lobe in the human pancreas rich in pancreatic polypeptide. Diabetologia 17:361–365
Gromada J, Franklin I, Wollheim CB (2007) α-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28:84–116
Ali Rachedi A, Varndell IM, Adrian TE, Gapp DA, Van Noorden S, Bloom SR, Polak JM (1984) Peptide YY (PYY) immunoreactivity is co-stored with glucagon-related immunoreactants in endocrine cells of the gut and pancreas. Histochemistry 80:487–491
Schmechel D, Marangos PJ, Brightman M (1978) Neuron specific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature 276:834–836
Wilkinson KD, Lee K, Desphande S, Duerksen-Hughes P, Boss JM, Pohl J (1989) The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246:670–673
Wiedenmann B, Franke WW (1985) Identification and localization of synaptophysin, an integral membrane glycoprotein of MW 38,000 characteristic of presynaptic vesicles. Cell 41:1017–1028
Ravazzola M, Orci L (1980) Glucagon and glicentin immunoreactivity are topologically segregated in the alpha granule of the human pancreatic A cell. Nature 286:66–67
Solcia E, Fiocca R, Capella C, Usellini L, Sessa F, Rindi G, Schwartz TW, Yanaihara N (1985) Glucagon- and PP-related peptides of intestinal L cells and pancreatic/gastric A or PP cells. Possible interrelationships of peptides and cells during evolution, fetal development and tumor growth. Peptides 6(Suppl 3):223–229
Goossens A, Heitz PU, Klöppel G (1991) Pancreatic endocrine cells and their non-neoplastic proliferations. In: Dayal Y (ed) Endocrine pathology of the gut and pancreas. CRC, Boca Raton, pp 69–104
Misugi K, Howel SL, Greider MH, Lacy PE, Sorenson GD (1970) The pancreatic beta cell. Demonstration with peroxidase-labelled antibody technique. Arch Pathol 89:97–102
Orci L, Ravazzola M, Amherdt M, Madsen O, Vassalli JD, Perrelet A (1985) Direct identification of prohormone conversion site in insulin secreting cells. Cell 42:671–681
Westermark P, Wernstedt C, Wilander E, Hayden DW, O’Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of diabetic cats are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 84:3881–3885
Orci L, Ravazzola M, Storch MJ, Anderson RG, Vassalli JD, Perrelet A (1987) Proteolytic maturation is a post-Golgi event which occurs in acidifying clathrin-coated secretory vesicles. Cell 49:865–868
Luft R, Efendic S, Hökfelt T, Johansson O, Arimura A (1974) Immunohistochemical evidence for the localisation of somatostatin-like immunoreactivity in a cell population of pancreatic islets. Med Biol 52:428–430
Like AA (1967) The ultrastructure of the secretory cell of the islets of Langerhans in man. Lab Invest 16:937–951
Grube D, Bohn R (1983) The microanatomy of human islets of Langerhans with special reference to somatostatin (D-) cells. Arch Histol Jpn 46:327–353
Wierup N, Yang S, McEvilly RJ, Mulder H, Sundler F (2004) Ghrelin is expressed in a novels endocrine cell type in developing rat islets and inhibits insulin secretion from INS-1 (832/13) cells. J Histochem Cytochem 52:301–310
Volante M, Allia E, Gugliotta P, Funaro A, Broglio F, Deghenghi R, Muccioli G, Ghigo E, Papotti M (2002) Expression of ghrelin and of the GH secretagogue receptors by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab 87:1300–1308
Rindi G, Necchi V, Savio A, Torsello A, Zoli M, Locatelli V, Raimondo F, Cocchi D, Solcia E (2002) Characterisation of gastric ghrelin cells in man and other mammals: studies in adult and fetal tissues. Histochem Cell Biol 117:511–519
Capella C, Hage E, Solcia E, Usellini L (1978) Ultrastructural similarity of endocrine-like cells of the human lung and some related cells of the gut. Cell Tissue Res 186:25–37
La Rosa S, Capella C, Lloyd RV (2002) Localization of myosin XVA in endocrine tumors of the gut and pancreas. Endocr Pathol 13:29–37
La Rosa S, Capella C, Lloyd RV (2005) Expression and role of myosins in pancreatic endocrine cells and related tumors. In: Loft MA (ed) Trends in pancreatic cancer research. Nova Science Publisher, Inc, Hauppauge, pp 23–39
Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, Schindler M, Cole SL, Bussolati G (2002) Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 440:461–475
Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20:1172–1182
Alberti KGMN, Zimmet PZ (1998) Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 15:539–553
American Diabetes Association (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197
Taplin CG, Barker JM (2008) Autoantibodies in type 1 diabetes. Autoimmunity 41:11–18
World Health Organization Expert Committee on diabetes mellitus. 2nd report. Technical report series. Geneva, WHO,1980
Zimet P (1982) Type 2 (non-insulin dependent) diabetes: an epidemiological overview. Diabetologia 22:399–411
Zimet PZ (1999) Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia 42:499–518
Buse JB, Polonsky KS, Burant C (2008) Type 2 diabetes mellitus. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR (eds) Williams textbook of endocrinology, 11th edn. WB Sauders, Philadelphia, pp 1329–1389
Eisenbarth GS, Polonsky KS, Buse JD (2008) Type 1 diabetes mellitus. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR (eds) Williams textbook of endocrinology, 11th edn. WB Sauders, Philadelphia, pp 1391–1416
Rubenstein AH (2001) Diabetes mellitus, carbohydrate metabolism, and lipid disorders. In: DeGroot LJ, Jamenson JL (eds) Endocrinology, 4th edn. WB Saunders, Philadelphia, pp 654–668
Gepts W (1965) Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14:619–633
Foulis AK, Stewart JA (1984) The pancreas in recent-onset type 1 (insulin-dependent) diabetes mellitus: insulin content of islets, insulitis and associated changes in the exocrine acinar tissue. Diabetologia 26:456–461
Klöppel G, Drenck CR, Oberholzer M, Heitz PU (1984) Morphometric evidence for a striking B-cell reduction at the clinical onset of type 1 diabetes. Virchows Arch A Pathol Anat Histopathol 403:441–452
Löhr M, Klöppel G (1987) Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin-dependent) diabetes mellitus and microangiopathy. Diabetologia 24:366–371
Henderson JR, Daniel PM, Fraser PA (1981) The pancreas as a single organ: the influence of the endocrine upon the exocrine part of the gland. Gut 22:158–167
Korc M, Owerbach D, Quinto C, Rutter WJ (1981) Pancreatic islet-acinar cell interaction: amylase messenger RNA levels are determined by insulin. Science 213:351–353
Gepts W, Le Compte PM (1981) The pancreatic islets in diabetes. Am J Med 70:105–115
Klöppel G, Clemens A (1998) Insulin-dependent diabetes mellitus: islet changes in relation to etiology and pathogenesis. Endocr Pathol 8:273–282
Lernmark A, Klöppel G, Stenger D, Vathanaprida C, Fält K, Landin-Olsson M, Baskin DG, Palmer JP, Gown AM, Petersen JS et al (1995) Heterogeneity of islet pathology in two infants with recent onset diabetes mellitus. Virchows Arch 465:631–640
Hanninen A, Jalkanen S, Salmi M, Toikkanen S, Nikolakaros G, Simell O (1992) Macrophages, T cell receptor usage, and endothelial cell activation in the pancreas at the onset of insulin-dependent diabetes mellitus. J Clin Invest 90:1901–1910
Conrad B, Weidmann E, Trucco G, Rudert WA, Behboo R, Ricordi C, Rodriquez-Rilo H, Finegold D, Trucco M (1994) Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature 33:749–760
Foulis AK (1996) The pathology of endocrine pancreas in type 1 (insulin-dependent) diabetes mellitus. APMIS 104:161–167
Rahier J, Goebbels RM, Henquin JC (1983) Cellular composition of the human diabetic pancreas. Diabetologia 24:336–371
Junker K, Egeberg J, Kromann H, Nerup J (1977) An autopsy study of the islets of Langerhans in acute-onset juvenile diabetes mellitus. APMIS 85:699–706
Hayden MR, Sowers JR (2007) Isletopathy in type 2 diabetes mellitus: implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress. Antioxid Redox Signal 9:891–910
Klöppel G (1984) Islet histopathology in diabetes mellitus. In: Klöppel G, Heitz PU (eds) Pancreatic pathology. Churchill Livingstone, Edinburg, pp 154–192
Clark A, Chargé SB, Badman MK, de Koning EJ (1996) Islet amyloid in type 2 (non-insulin-dependent) diabetes. APMIS 104:12–18
Bell ET (1952) Hyalinization of the islets of Langerhans in diabetes mellitus. Diabetes 1:341–344
Hull RL, Westermark GT, Westermark P, Kahn SE (2004) Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Endocrinol Metab 89:3629–3643
Nishi M, Sanke T, Nagamatsu S, Bell GI, Steiner DF (1990) Islet amyloid polypeptide. A new beta cell secretory product related to islet amyloid deposits. J Biol Chem 265:4173–4176
Lukinius A, Wilander E, Westermark GT, Engström U, Westermark P (1989) Co-localization of islet amyloid polypeptide and insulin in the B-cell secretory granules of the human pancreatic islets. Diabetologia 32:240–244
Finzi G, Franzi F, Placidi C, Acquati F, Palumbo E, Russo A, Taramelli R, Sessa F, La Rosa S (2008) BACE2 is stored in secretory granules of mouse and rat pancreatic β-cells. Ultrastruct Pathol 32:246–251
Miklossy J, Qing H, Radenovic A, Kis A, Vileno B, Làszlo F, Miller L, Martins RN, Waeber G, Mooser V, Bosman F, Khalili L, Darbinian-Sralissian N, McGeer PL (2009) Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging in press
Solcia E, Klöppel G, Capella C (1997) Tumor-like conditions of the endocrine pancreas. In: Rosai J, Sobin LH (eds) Tumors of the pancreas. Atlas of tumor pathology. Armed Forces Institute of Pathology, Washington, pp 237–246
Ray MB, Zumwalt R (1986) Islet-cell hyperplasia in genetic deficiency of alpha-1-proteinase inhibitor. Am J Clin Pathol 85:681–687
Weidenhein KM, Hinchey WW, Campbell WG Jr (1983) Hyperinsulinemic hypoglycemia in adults with islet cell hyperplasia and degranulation of exocrine cells of the pancreas. Am J Clin Pathol 79:14–24
Ellison EH, Wilson SD (1967) The Zollinger-Ellison syndrome uptade. Surg Clin North Am 47:1115–1124
Verner JV, Morrison AB (1974) Endocrine pancreatic islet disease with diarrhea. Report of a case due to diffuse hyperplasia of nonbeta islet tissue with a review of 54 additional cases. Arch Intern Med 133:492–499
Solcia E, Capella C, Buffa R et al (1986) Antigenic markers of neuroendocrine tumors: their diagnostic and prognostic value. In: Fenoglio CM, Weinstein RS, Kaufman N (eds) New concepts in neoplasia as applied to diagnostic pathology. Williams & Wilkins, Baltimore, pp 242–261
Solcia E, Capella C, Riva C, Rindi G, Polak JM (1988) The morphology and neuroendocrine profile of pancreatic epithelial VIPomas and extrapancreatic, VIP-producing, neurogenic tumors. Ann N Y Acad Sci 527:508–517
Kahn E, Anderson VM, Greco MA, Magrid M (1995) Pancreatic disorders in pediatric acquired immunodeficiency syndrome. Hum Pathol 26:765–770
Verloes A, Massart B, Dehlleux I, Langhendries JP, Koulischer L (1995) Clinical overlap of Beckwith-Wiedenmann, Pelman and Simpson-Golabi-Behmel syndromes: a diagnostic pitfall. Clin Genet 47:257–262
Hardwick DF, Dimmick JE (1976) Metabolic cirrhosis of infancy and early childhood. In: Rosenberg HS, Bolande RP (eds) Perspectives in pediatric pathology, vol 3. Year Book Med Pebl, Chicago, pp 103–144
Zellweger H (1979) Cerebro-hepato-renal syndrome. In: Bergsma D (ed) Birth defects compendium, 2nd edn. Alan R Liss, New York, pp 178–196
Rosemberg AM, Hawort JC, Degroot GW, Trevenen CL, Rechler MM (1980) A case of leprechaunism with severe hyperinsulinemia. Am J Dis Child 134:170–175
Stefan Y, Bordi C, Grasso S, Orci L (1985) Beckwith-Wiedemann syndrome: a quantitative, immunohistochemical study of the pancreatic islet cell populations. Diabetologia 28:914–919
Laidlaw GF (1938) Nesioblastoma, the islet tumor of the pancreas. Am J Pathol 2:125–134
Aynsley-Green A, Polak JM, Bloom SR, Gough MH, Kelling J, Ashcroft SJ, Turner RC, Baum JD (1981) Nesidioblastosis of the pancreas: definition of the syndrome and the management of the severe neonatal hyperinsulinemic hypoglycemia. Arch Dis Child 56:469–508
Stanley CA, Baker L (1999) The causes of neonatal hypoglycemia. N Engl J Med 340:1200–1201
Thornton PS, Alter CA, Katz LE, Baker L, Stanley CA (1993) Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr 123:637–643
De Lonlay-Debeney P, Poggi-Travert F, Fournet JC, Sempoux C, Vici CD, Brunelle F, Touati G, Rahier J, Junien C, Nihoul-Fékété C, Robert JJ, Saudubray JM (1999) Clinical features of 52 neonates with hyperinsulinism. N Engl J Med 340:1169–1175
Shilyansky J, Fisher S, Cutz E, Perlman K, Filler RM (1997) Is 95% pancreatectomy the procedure of choice for treatment of persistent hyperinsulinemic hypoglycemia of the neonate? J Pediatr Surg 32:342–346
Reinecke-Lüthge A, Koschoreck F, Klöppel G (2000) The molecular basis of persistent hyperinsulinemic hypoglycemia of infancy and its pathologic substrates. Virchows Arch 436:1–5
Dunne MJ, Kane C, Shephered RM, Sanchez JA, James RF, Johnson PR, Aynsley-Green A, Lu S, Clement JP, Lindley KJ, Seino S, Aguilar-Bryan L (1997) Familial persistent hyperinsulinemic hypoglycemia of infancy and mutations in the sulfonylurea receptor. N Engl J Med 336:703–706
Nestorowicz A, Inagaki N, Gonoi T, Schoor KP, Wilson BA, Glaser B, Landau H, Stanley CA, Thornton PS, Seino S, Permutt MA (1997) A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism. Diabetes 46:1743–1748
Thomas PM, Cote GJ, Wohlik N, Haddad B, Mathew PM, Rabl W, Aguilar-Bryan L, Gagel RF, Bryan J (1995) Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 268:426–429
Dunne MJ, Cosgrove KE, Shepherd RM, Aynsley-Green A, Lindley KJ (2004) Hyperinsulinism in infancy: from basic science to clinical disease. Physiol Rev 84:239–275
Biagiotti L, Proverbio MC, Bosio L, Gervasi F, Rovida E, Cerioni V, Bove M, Valin PS, Albarello L, Zamproni I, Grassi S, Doglioni C, Mora S, Chiumello G, Biunno I (2007) Identification of two novel frameshift mutations in the KCNJ11 gene in two Italian patients affected by congenital hyperinsulinism of infancy. Exp Mol Pathol 83:59–64
Gloyn AL, Noordam K, Willemsen MA, Ellard S, Lam WW, Campbell IW, Midgley P, Shiota C, Buettger C, Magnuson MA, Matschinsky FM, Hattersley AT (2003) Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes 52:2433–2440
Wabitsh M, Lahr G, Van de Bunt M, Marchant C, Lindner M, von Puttkamer J, Fenneberg A, Debatin KM, Klein R, Clark A, Gloyn AL (2007) Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy. Diabet Med 24:1393–1399
De Lonlay P, Fournet JC, Rahier J, Gross-Morand MS, Poggi-Travert F, Foussier V, Bonnefont JP, Brusset MC, Brunelle F, Robert JJ, Nihoul-Fékété C, Saudubray JM, Junien C (1997) Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy. J Clin Invest 100:802–807
Meissner T, Beinbrech B, Mayatepek E (1999) Congenital hyperinsulinism: molecular basis of a heterogeneous disease. Hum Mutat 13:351–361
Jaffe R, Hashida Y, Yunis EJ (1980) Pancreatic pathology in hyperinsulinemic hypoglycemia of infancy. Lab Invest 42:356–365
Goossens A, Gepts W, Saudubray JM, Bonnefont JP, Nihoul-Fekete C, Heitz PU, Klöppel G (1989) Diffuse and focal nesidioblastosis: a clinicopathological study of 24 patients with persistent neonatal hyperinsulinemic hypoglycemia. Am J Surg Pathol 13:766–775
Witte DP, Greider MH, Deschryver-Kecskement K, Kissane JM, White NH (1984) The juvenile human endocrine pancreas: normal vs idiopathic hyperinsulinemic hypoglycemia. Semin Diagn Pathol 1:30–42
Sempoux C, Guiot Y, Lefevre A, Nihoul-Fékété C, Jaubert F, Saudubray JM, Rahier J (1998) Neonatal hyperinsulinemic hypoglycemia: heterogeneity of the syndrome and keys for differential diagnosis. J Clin Endocrinol Metab 83:1455–1461
Lyonnet S, Bonnefont JP, Saudubray JM, Nihoule-Fekete C, Brunelle F (1989) Localization of focal lesion permitting partial pancreatectomy in infants. Lancet 2:671
Sempoux C, Guiot Y, Dahan K, Moulin P, Stevens M, Lambot V, de Lonlay P, Fournet JC, Junien C, Jaubert F, Nihoul-Fekete C, Saudubray JM, Rahier J (2003) The focal form of persistent hyperinsulinemic hypoglycemia in infancy. Morphological and molecular studies show structural and functional differences with insulinoma. Diabetes 52:784–794
Falkmer S, Askensten U (1988) Disturbed growth of the endocrine pancreas. In: Levebre PJ, Pipeleers DG (eds) The pathology of the endocrine pancreas in diabetes. Springer, Berlin, pp 125–140
Dahms BB, Landing BH, Blastovics M, Roe TF (1980) Nesidioblastosis and other islet cell abnormalities in hyperinsulinemic hypoglycemia of childhood. Hum Pathol 11:641–649
Gould VE, Memoli VA, Dardi LE, Gould NS (1983) Nesidiodysplasia and nesidioblastosis of infancy: structural and functional correlation with the syndrome of hyperinsulinemic hypoglycemia. Pediatr Pathol 1:7–31
Rahier J, Falt K, Muntefering H, Becker K, Gepts W, Falkmer S (1984) The basis structural lesion of persistent neonatal hypoglycemia with hyperinsulinism: deficiency of pancreatic D-cells or hyperactivity of B-cells? Diabetologia 26:282–289
Sempoux C, Guiot Y, Dubois D, Nollevaux MC, Saudubray JM, Nihoul-Fekete C, Rahier J (1998) Pancreatic B-cell proliferation in persistent hyperinsulinemic hypoglycemia of infancy: an immunohistochemical study of 18 cases. Mod Pathol 11:444–449
Kollee LA, Monnens LA, Cejka V, Wilms RM (1978) Persistent neonatal hypoglycemia due to glucagon deficiency. Arch Dis Child 53:422–424
Jabri AL, Bayard C (2004) Nesidioblastosis associated with hyperinsulinemic hypoglycemia in adults: review of the literature. Eur J Int Med 15:407–410
Klöppel G, Anlauf M, Raffel A, Perren A, Knoefel WT (2008) Adult diffuse nesidioblastosis: genetically or environmentally induced? Hum Pathol 39:3–8
Anlauf M, Wieben D, Perren A, Sipos B, Komminoth P, Raffel A, Kruse ML, Fottner C, Knoefel WT, Möning H, Heitz PU, Klöppel G (2005) Persistent hyperinsulinemic hypoglicemia in 15 adults with diffuse nesidioblastosis. Diagnostic criteria, incidence, and characterization of β-cell lineage. Am J Surg Pathol 29:524–533
Klöppel G, Willemer S, Stamm B, Häcki WH, Heitz PU (1986) Pancreatic lesions and hormonal profile of pancreatic tumors in multiple endocrine neoplasia type I. An immunocytochemical study of nine patients. Cancer 57:1824–1832
Rindi G, Terenghi G, Westermark G, Westermark P, Moscoso G, Polak JM (1991) Islet amyloid polypeptide (IAPP) in proliferating pancreatic B cells during development, hyperplasia and neoplasia in man and mouse. Am J Pathol 138:1321–1334
Rindi G, Bishop AE, Murphy D, Solcia E, Hogan B, Polak JM (1988) A morphological analysis of endocrine tumour genesis in pancreas and anterior pituitary of AVP/SV40 transgenic mice. Virchows Arch A Pathol Anat Histopathol 412:255–266
Rindi G, Grant SG, Yiangou Y, Ghatei MA, Bloom SR, Bautch VL, Solcia E, Polak JM (1990) Development of neuroendocrine tumours in the gastrointestinal tract of transgenic mice: heterogeneity of hormone expression. Am J Pathol 136:1349–1363
Rindi G, Efrat S, Gathei MA, Bloom SR, Solcia E, Polak JM (1991) Glucagonomas of transgenic mice express a wide range of general neuroendocrine markers and bioactive peptides. Virchows Arch A Pathol Anat Histopathol 419:115–129
Bonner-Weir S, Baxter LA, Schuppin GT, Smith FE (1993) A second pathway for regeneration of adult exocrine and endocrine pancreas. Diabetes 42:1715–1720
Smith FE, Rosen KM, Villa-Komaroff L, Weir GC, Bonner-Weir S (1991) Enhanced insulin-like growth factor I gene expression in regenerating rat pancreas. Proc Natl Acad Sci USA 88:6152–6156
Porta EA, Stein AA, Patterson P (1964) Ultrastructural changes of the pancreas and liver in cystic fibrosis. Am J Clin Pathol 42:451–465
Cubilla AL, Fitzgerald PJ (1984) Tumors of the exocrine pancreas. Atlas of tumor pathology. Armed Forces Institute of Pathology, Washington
Bockman DE, Boydston WR, Anderson WC (1982) Origin of tubular complexes in human chronic pancreatitis. Am J Surg 144:243–249
Goudswaard WB, Houthoff HJ, Koudstaal J, Zwierstra RP (1986) Nesidioblastosis and endocrine hyperplasia of the pancreas: a secondary phenomenon. Hum Pathol 17:46–54
Rindi G (1993) Transgenic models of endocrine tumors. In: Polak JM (ed) Diagnostic histopathology of neuroendocrine tumors. Churchill-Livingstone, Edinburg, pp 67–89
Solcia E, Sessa F, Rindi G et al (1991) Pancreatic endocrine tumors: nonfunctioning tumors and tumors with uncommon function. In: Dayal Y (ed) Endocrine pathology of the gut and pancreas. CRC, Boca Raton, pp 105–132
Solcia E, Klöppel G, Capella C (1997) Tumors of the endocrine pancreas. In: Rosai J, Sobin LH (eds) Tumors of the pancreas. Atlas of tumor pathology, 3rd edn. Armed Forces Institute of Pathology, Washington, pp 145–209
Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, Lorang D, Libutti SK, Chandrasekharappa SC, Marx SJ, Spiegel AM, Collins FS (2001) A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA 98:118–123
Perren A, Anlauf M, Henopp T, Rudolph T, Schmitt A, Raffel A, Gimm O, Weihe E, Knoefel WT, Dralle H, Heitz PU, Komminoth P, Klöppel G (2007) Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab 92:1118–1128
Nicholls AG (1902) Simple adenoma of the pancreas arising from an island of Langerhans. J Med Res 8:385–395
Heitz PU (1984) Pancreatic endocrine tumors. In: Klöppel G, Heitz PU (eds) Pancreatic pathology. Churchill-Livingstone, Edinburgh, pp 206–232
Capella C, Heitz PU, Höfler H, Solcia E, Klöppel G (1995) Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 425:547–560
Kimura N, Miura W, Noshiro T, Miura Y, Ookuma T, Nagura H (1994) Ki-67 is an indicator of progression of neuroendocrine tumors. Endocr Pathol 5:223–228
DeLellis RA (1995) Does the evaluation of proliferative activity predict malignancy or prognosis in endocrine tumors? Hum Pathol 26:131–133
Lloyd RV (1995) Proliferative markers in the study of endocrine diseases. Endocr Pathol 6:83–86
Pelosi G, Zamboni G (1996) Proliferation markers and their uses in the study of endocrine tumors. Endocr Pathol 7:103–119
Pelosi G, Zamboni G, Doglion C, Rodella S, Bresaola E, Iacono C, Serio G, Iannucci A, Scarpa A (1992) Immunodetection of proliferating cell nuclear antigen assesses the growth fraction and predicts malignancy in endocrine tumors of the pancreas. Am J Surg Pathol 16:1215–1225
La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, Rindi G, Solcia E (1996) Prognostic criteria in nonfunctioning pancreatic endocrine tumors. Virchows Arch 429:323–333
Lloyd RV (1998) Utility of Ki-67 as a prognostic marker in pancreatic endocrine neoplasms. Am J Clin Pathol 109:245–247
Chaudhry A, Öberg K, Wilander E (1992) A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumour Biol 13:27–35
Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P, Iacono C, Serio G, Zamboni G (1996) Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy. A comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variable. Hum Pathol 27:1124–1134
Pelosi G, Pasini F, Bresaola E, Bogina G, Pederzoli P, Biolo S, Menard S, Zamboni G (1997) High-affinity monomeric 67-kD laminin receptors and prognosis in pancreatic endocrine tumors. J Pathol 183:62–69
Clarke MR, Baker EV, Weyant RJ, Hill L, Carty SE (1997) Proliferative activity in pancreatic endocrine tumors: association with function, metastases, and survival. Endocr Pathol 8:181–187
Gentil-Perret AG, Mosnier JF, Buono JP, Berthelot P, Chipponi J, Balique JG, Cuilleret J, Dechelotte P, Boucheron S (1998) The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. Am J Clin Pathol 109:286–293
Chang HJ, Batts KP, Lloyd RV, Sebo TJ, Thompson GB, Lohse CM, Pankratz SV (2000) Prognostic significance of p27, Ki-67, and topoisomerase IIα expression in clinically nonfunctioning pancreatic endocrine tumors. Endocr Pathol 11:229–241
Schmitt AM, Anlauf M, Rousson V, Schmid S, Kofler A, Riniker F, Bauersfeld J, Braghorn A, Probst-Hensh NM, Moch H, Heitz PU, Klöppel G, Komminoth P, Perren A (2007) WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 31:1677–1682
Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A, Falconi M (2008) Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 19:903–908
Faggiano A, Mansueto G, Ferolla P, Milone F, del Basso de Caro ML, Lombardi G, Colao A, De Rosa G (2008) Diagnostic and prognostic implications of the World Health Organization classification of neuroendocrine tumors. J Endocrinol Invest 31:216–223
Jamail M, Chetty R (2008) Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and value of Ki67 immunostaining. Endocr Pathol 19(4):282–288
Pape UF, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M, Willich SN, Wiedenmann B (2008) Prognostic factors of long term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 15(4):1083–1097
La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A, Doglioni C, Capella C, Solcia E (2009) Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol 40:30–40
Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, Klimstra DS (2002) Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20:2633–2642
Alexiev BA, Drachenberg CB, Papadimitriou JC (2007) Endocrine tumors of the gastrointestinal tract and pancreas: grading, tumor size and proliferation index do not predict malignant behavior. Diagn Pathol 2:28
Piani C, Franchi GM, Cappelletti C, Scavini M, Albarello L, Zerbi A, Arcidiacono PG, Bosi E, Manzoni MF (2008) Cytological Ki-67 in pancreatic endocrine tumours: an opportunity for pre-operative grading. Endocr Relat Cancer 15:175–181
Desphande V, Fernandez-del Castillo C, Muzikansky A, Deshpande A, Zukerberg L, Warshaw AL, Lauwers GY (2004) Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol 28:1145–1153
Ali A, Serra S, Asa SL, Chetty R (2006) The predictive value of Ck19 and Cd99 in pancreatic endocrine tumors. Am J Surg Pathol 30:1588–1594
La Rosa S, Rigoli E, Uccella S, Novario R, Capella C (2007) Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours. Histopathology 50:597–606
Diaz-Rubio JL, Duarte-Rojo A, Saqui-Salces M, Gamboa-Dominquez A, Robles-Diaz G (2004) Cellular proliferative fraction measured with topoisomerase II alpha predicts malignancy in endocrine pancreatic tumors. Arch Pathol Lab Med 128:426–429
Ohike N, Morohoshi T (2001) Immunohistochemical analysis of cyclooxygenase (COX)-2 expression in pancreatic endocrine tumors: association with tumor progression and proliferation. Pathol Int 51:770–777
Grabowski P, Griss S, Arnold CN, Hörsch D, Göke R, Arnold R, Heine B, Stein H, Zeitz M, Scherübl H (2005) Nuclear surviving is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease. Neuroendocrinology 81:1–9
Rubbia-Brandt L, Terris B, Giostra E, Dousset B, Morel P, Pepper MS (2004) Lymphatic vessel density and vascular endothelial growth factor-C expression correlate with malignant behaviour in human pancreatic endocrine tumors. Clin Cancer Res 10:6919–6928
Solcia E, Klöppel G, Sobin LH et al (2000) Histological typing of endocrine tumours. WHO International Histological Classification of Tumours, 2nd edn. Springer, Berlin
DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) World Health Organization Classification of Tumours. Pathology & genetics of tumours of endocrine organs. IARC, Lyon
Formica V, Wotherspoon A, Cunningham D, Norman AR, Sirohi B, Oates J, Chong G (2007) The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. Br J Cancer 96:1178–1182
Bajetta E, Catena L, Procopio G, Bichisao E, Ferrari L, Della Torre S, De Dosso S, Iacobelli S, Buzzoni R, Mariani L, Rosai J (2005) Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann Oncol 16:1374–1380
Pape UF, Jann H, Muller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Rocken C, Rindi G, Wiedenmann B (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113:256–265
Fischer L, Kleeff J, Esposito I, Hinz U, Zimmermann A, Friess H, Buchler MW (2008) Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 95:627–635
Rindi G, Klöppel G, Alhman H, Caplin M, Couveland A, de Herder WW, Eriksson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNichol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virschows Arch 449:395–401
Singh R, Basturtk O, Klimstra DS, Zamboni G, Chetty R, Hussain S, La Rosa S, Yilmaz A, Capelli P, Capella C, Cheng JD, Adsay NV (2006) Lipid-rich variant of pancreatic endocrine neoplasms. Am J Surg Pathol 30:194–200
Volante M, La Rosa S, Costellano I, Finzi G, Capella C, Bussolati G (2006) Clinico-pathological features of a series of 11 oncocytic endocrine tumours of the pancreas. Virchows Arch 448:545–551
Zee SY, Hochwald SN, Conlon KC, Brennan MF, Klimstra DS (2005) Pleomorphic pancreatic endocrine neoplasms. A variant commonly confused with adenocarcinoma. Am J Surg Pathol 29:1194–1200
Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, Stolte M, Capella C, Bordi C, Solcia E (1999) ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116:532–542
Ferrone C, Tang LH, Tomlison J, Gonen M, Hochwald SN, Brennan MF, Klimstra DS, Allen PJ (2007) Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 25:5609–5615
Hruban RH, Bishop Pitman M, Klimstra DS (2007) Tumors of the endocrine pancreas. In: Silverberg SG, Sobin LH (eds) Tumors of the pancreas. Atlas of tumor pathology, 4th edn. American registry of Pathology, Washington, pp 251–304
Morohoshi T, Kanda M, Horie A, Chott A, Dreyer T, Klöppel G, Heitz PU (1987) Immunocytochemical markers of uncommon pancreatic tumors. Acinar cell carcinoma, pancreatoblastoma and solid-cystic (papillary-cystic) tumor. Cancer 59:739–747
La Rosa S, Franzi F, Marchet S, Finzi G, Clerici M, Vigetti D, Chiaravalli AM, Sessa F, Capella C (2009) The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia. Virchows Arch 454(2):133–142
Klimstra DS, Wenig BM, Adair CF, Heffess CS (1995) Pancreatoblastoma. A clinicopathologic study and review of the literature. Am J Surg Pathol 19:1371–1389
Lam KY, Lo CY (1997) Pancreatic endocrine tumour: a 22-year clinico-pathological experience with morphological, immunohistochemical observation and review of the literature. Eur J Surg Oncol 23:36–42
Broughan TA, Leslie JD, Soto JM, Hermann RE (1986) Pancreatic islet cell tumours. Surgery 99:671–678
Klöppel G, Heitz PU (1988) Pancreatic endocrine tumors. Pathol Res Pract 183:155–168
Koolie H, Whitte TT (1972) Pancreatic islet beta cell tumors and hyperplasia: experience in 14 Seattle hospitals. Ann Surg 175:326–335
Howard JN, Moss NH, Rhoads JE (1950) Hyperinsulinism and islet cell tumors of the pancreas with 398 recorded tumors. Surg Gynecol Obstet 90:417–455
Stefanini P, Carbono M, Patrassi N (1974) Beta islet cell tumours of the pancreas, results of a statistical study on 1067 cases collected. Surgery 75:597–609
Lo CY, Lam KY, Kung AW, Lam KS, Tung PH, Fan ST (1997) Pancreatic insulinomas. A 15 years experience. Arch Surg 132:926–930
Grant CS (1996) Gastrointestinal endocrine tumours. Insulinoma. Baillieres Clin Gastroenterol 10:645–671
Boden G (1987) Insulinoma and glucagonoma. Semin Oncol 14:253–262
Rothmund M, Angelini L, Brunt LM, Farndon JR, Geelhoed G, Grama D, Herfarth C, Kaplan EL, Largiader F, Morino F et al (1990) Surgery for benign insulinoma: an international review. World J Surg 14:398–399
Le Bodic MF, Heymann MF, Lecomte M, Berger N, Berger F, Louvel A, De Micco C, Patey M, De Mascarel A, Burtin F, Saint-Andre JP (1996) Immunohistochemical study of 100 pancreatic tumors in 28 patients with multiple endocrine neoplasia type I. Am J Surg Pathol 20:1378–1384
Toshimori H, Narita R, Nakazato M, Asai J, Mitsukawa T, Kangawa K, Matsuo H, Takahashi K, Matsukura S (1991) Islet amyloid polypeptide in insulinoma and islets of the pancreas of non-diabetic and diabetic subjects. Virchows Arch A Pathol Anat Histopathol 418:411–417
Liu TH, Tseng HC, Zhu Y, Zhong SX, Chen J, Cui QC (1985) Insulinoma. An immunohistochemical and morphologic analysis of 95 cases. Cancer 56:1420–1429
Mukai K, Grotting JC, Greider MH, Rosai J (1982) Retrospective study of 77 pancreatic endocrine tumors using the immunoperoxidase method. Am J Surg Pathol 6:387–399
Klöppel G, Höfler H, Heitz PU (1993) Pancreatic endocrine tumors in man. In: Polak JM (ed) Diagnostic histopathology of neuroendocrine tumors. Churchill-Livingstone, Edinburgh, pp 91–121
Azzoni C, D’Adda T, Tamburrano G, Costelli C, Madsen OD, Scopsi L, Bordi C (1998) Functioning human insulinomas. An immunohistochemical analysis of intracellular insulin processing. Virchows Arch 433:495–504
Pavelic K, Hrascan R, Kapitanovic S, Vranes Z, Cabrijan T, Spaventi S, Korsic M, Krizanac S, Li YQ, Stambrook P, Gluckman JL, Pavelic ZP (1996) Molecular genetics of malignant insulinoma. Anticancer Res 16:1707–1718
Berger M, Bordi C, Cupper HJ, Berchtold P, Gries FA, Münterfering H, Sailer R, Zimmermann H, Orci L (1983) Functional and morphologic characterization of human insulinomas. Diabetes 32:921–931
Creutzfeldt W, Arnold R, Creutzfeldt C, Deuticke U, Frerichs H, Track NS (1973) Biochemical and morphological investigations of 30 human insulinomas. Correlation between the tumor content of insulin and proinsulin-like components and the histological and ultrastructural appearance. Diabetologia 9:217–231
Kindmark H, Sundin A, Granberg D, Dunder K, Skogseid B, Janson ET, Welin S, Öberg K, Eriksson B (2007) Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. Med Oncol 24:330–337
Ruttman E, Klöppel G, Klehn M, Kiehn M, Heitz PU (1980) Pancreatic glucagonoma with and without the syndrome. Immunocytochemical study of 5 tumor cases and review the literature. Virchows Arch A Pathol Anat Histopathol 388:51–67
Soga J, Yakuwa Y (1998) Glucagonoma/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases. J Hepatobiliary Pancreat Surg 5:312–319
Hamid QA, Bishop AE, Sikri KL, Varndell IM, Bloom SR, Polak JM (1986) Immunocytochemical characterization of 10 pancreatic tumours, associated with the glucagonoma syndrome, using antibodies to separate regions of the pro-glucagon molecule and other neuroendocrine markers. Histopathology 10:119–133
Polak JM, Bloom SR (1991) Glucagon-producing tumors and the glucagonoma syndrome. In: Dayal Y (ed) Endocrine pathology of the gut and pancreas. CRC, Boca Raton, pp 227–240
Bordi C, Ravazzola M, Baetens D, Gorden P, Unger RH, Orci L (1979) A study of glucagonomas by light and electron microscopy and immunofluorescence. Diabetes 28:925–936
Creutzfeldt W (1977) Endocrine tumors of the pancreas. In: Volk BW, Wellman KF (eds) The diabetic pancreas. Plenum, New York, pp 551–590
Mullan MH, Gauger PG, Thompson NW (2001) Endocrine tumours of the pancreas: review and recent advances. ANZ J Surg 71:475–482
Wynick D, Williams SJ, Bloom SR (1988) Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med 319:605–607
Vinik AI, Strodel WE, Eckauser FE, Moattari AR, Lloyd RV (1987) Somatostatinoma, PPoma, neurotensinoma. Semin Oncol 14:263–281
Harris GJ, Tio F, Cruz AB (1987) Somatostatinoma: a case report and review of the literature. J Surg Oncol 36:8–16
Levi S, Bjarnnason I, Swinson CM, Polak JM, Murray W, Levi AJ (1988) Malignant pancreatic somatostatinoma in a patient with dermatitis herpetiformis and coeliac disease. Digestion 39:1–6
Konomi K, Chjiiwa K, Katsuta T, Yamaguchi K (1990) Pancreatic somatostatinoma: a case report and review of the literature. J Surg Oncol 43:259–265
Ohasawa H, Kanatsuka A, Tokuyama Y, Yamaguchi T, Makino H, Yoshida S, Horie H, Mikata A, Kohen Y (1991) Amyloid protein in somatostatinoma differs from human islet amyloid polypeptide. Acta Endocrinol 124:45–53
Stavri GT, Pritchard GA, Williams EJ, Stamatakis JD (1992) Somatostatinoma of the pancreas with hypercalcemia. A case report. Eur J Surg Oncol 18:298–300
Roy J, Pompilio M, Yvin JL (1993) Somatostatinoma pancréatique. Une nouvelle observation. La Presse Médicale 22:1012
Dominioni L, Dionigi R, Benevento A, Capella C, La Rosa S, Roncari G, Garancini S (1995) Very late recurrence of a somatostatin-cell tumor of the head of the pancreas. Pancreas 10:417–419
Maki M, Kaneko Y, Ohta Y, Nakamura T, Machinami R, Kurokawa K (1995) Somatostatinoma of the pancreas associated with von Hippel-Lindau disease. Intern Med 34:661–665
Anene C, Thompson JS, Saigh J, Badakhsh S, Ecklund RE (1995) Somatostatinoma; atypical presentation of a rare pancreatic tumor. Am J Gastroenterol 90:819–821
Barbato A, Roviello F, De Stefano A, Marrelli D, Messano A, Guarnieri A, Pinto E (1996) A case of pancreatic somatostatinoma. Minerva Chir 51:475–479
Roy J, Pompilio M, Samana G (1996) Pancreatic somatostatinoma and MEN1. Apropos of a case. Review of the literature. Am Endocrinol 57:71–76
Sessa F, Arcidiacono M, Valenti L, Solcia M, Di Maggio E, Solcia E (1997) Metastatic psammomatous somatostatinoma of the pancreas causing severe ketoacidotic diabetes cured by surgery. Endocr Pathol 8:327–333
Garbrecht N, Anlauf M, Schmitt A, Henopp T, Sipos B, Raffel A, Eisenberger CF, Knoefel WT, Pavel M, Fottner C, Musholt TJ, Rinke A, Arnold R, Berndt U, Plöckinger U, Wiedenmann B, Moch H, Heitz PU, Komminoth P, Perren A, Klöppel G (2008) Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 15:229–241
Sugimoto F, Sekiya T, Saito M, Iiai T, Suda K, Nozawa A, Nakazawa T, Ishizaki T, Ikarashi T (1998) Calcitonin-producing pancreatic somatostatinoma: report of a case. Surg Today 28:1279–1282
Cantor AM, Rigby CC, Beck PR, Mangion D (1982) Neurofibromatosis, pheochromocytomas, and somatostatinoma. Br J Med 185:1618–1619
La Rosa S, Sessa F, Leone BE, Rindi G, Capella C (1997) Clinico-pathologic profile of duodenal and pancreatic somatostatin-cell tumors. Mod Pathol 10:50A
Soga J, Yakuwa Y (1998) Vipoma/diarrheagenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 17:389–400
Capella C, Polak JM, Buffa R, Tapia FJ, Heitz P, Usellini L, Bloom SR, Solcia E (1983) Morphologic patterns and diagnostic criteria of VIP-producing endocrine tumors. A histologic, histochemical, ultrastructural and biochemical study of 32 cases. Cancer 52:1860–1874
Morrison AB (1978) Islet cell tumors and the diarrheogenic syndrome. In: Fitzgerald PJ, Morrison AB (eds) The pancreas. Williams & Wilkins, Baltimore, pp 185–207
Maton PN, O’Dorisio TM, O’Dorisio MS et al (1986) Successful therapy of pancreatic cholera with the long-acting somatostatin analogue SMS 201-995: relation between plasma concentration of drug and clinical and biochemical responses. Scand J Gastroenterol 21(Suppl 119):181–186
Fox PS, Hoffmann JW, Wilson SD, DeCosse JJ (1974) Surgical management of the Zollinger-Ellison syndrome. Surg Clin North Am 54:395–407
Buchanan KD, Johnson CF, O’Hare M et al (1986) Neuroendocrine tumors. A European view. Am J Med 81(Suppl 6B):14–22
Stamm B, Hacki WH, Klöppel G et al (1991) Gastrin-producing tumors and the Zollinger-Ellison syndrome. In: Dayal Y (ed) Endocrine tumors of the gut and pancreas. CRC, Boca Raton, pp 155–194
Jensen RT, Doppman JL, Gardner JD (1986) Gastrinoma. In: Go VL, Gardner JD, Brooks FP, Lebenthal E, Di Magno EP, Scheele GA (eds) The exocrine pancreas: biology, pathobiology, and disease. Raven, New York, pp 727–744
Stabile BE, Morrow DJ, Passaro E Jr (1984) The gastrinoma triangle: operative implications. Am J Surg 147:25–31
Creutzfeldt W, Arnold R, Creutzfeldt C, Track NS (1975) Pathomorphologic, biochemical, and diagnostic aspects of gastrinomas (Zollinger-Ellison syndrome). Hum Pathol 6:47–76
Solcia E, Capella C, Buffa R et al (1980) Pathology of the Zollinger-Ellison syndrome. Prog Surg Pathol 1:119–133
Gurevich L, Kazantseva I, Isakov VA, Korsakova N, Egorov A, Kubishkin V, Bulgakov G (2003) The analysis of immunophenotype of gastrin-producing tumors of the pancreas and gastrointestinal tract. Cancer 98:1967–1976
Weber HC, Venzon DY, Lin TY, Fishbein VA, Orbuch M, Strader DB, Gibril F, Metz DC, Fraker DL, Norton JA, Jensen R (1995) Determinants of survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 108:1637–1649
Anlauf M, Garbrecht N, Henopp T, Schmitt A, Schlenger R, Raffel A, Krausch M, Gimm O, Eisenberger CF, Knoefel WT, Dralle H, Komminoth P, Heitz PU, Perren A, Klöppel G (2006) Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol 12:54440–54446
Mao C, el Attar A, Domenico DR, Kim K, Howard JM (1998) Carcinoid tumors of the pancreas. Status report based on two cases and review of the world’s literature. Int J Pancreatol 23:153–164
Soga J (2005) Carcinoids of the pancreas. An analysis of 156 cases. Cancer 104:1180–1187
Dollinger MR, Ratner LH, Shamoian CA, Blackbourne BD (1967) Carcinoid syndrome associated with pancreatic tumors. Arch Intern Med 120:575–580
Patchefsky AS, Solit R, Phillips LD, Craddock M, Harrer MV, Cohn HE, Kowlessar OD (1972) Hydroxyindole-producing tumors of the pancreas-carcinoid islet cell tumor and oat cell carcinoma. Ann Intern Med 77:53–61
Van Der Sluys Veer J, Choufoer JC et al (1964) Metastasizing islet-cell tumour of the pancreas associated with hypoglycemia and carcinoid syndrome. Lancet 1:1416–1419
Dayal Y, Lin HD, Tallberg K, Reichlin S, DeLellis RA, Wolfe HJ (1986) Immunocytochemical demonstration of growth hormone – releasing factor in gastrointestinal and pancreatic endocrine tumors. Am J Clin Pathol 85:13–20
Asa SL, Kovacs K, Thoner MD, Leong DA, Rivier J, Vale W (1985) Immunohistological localization of growth-hormone-releasing hormone in human tumors. J Clin Endocrinol Metab 60:423–427
Bostwick DG, Quan R, Hoffman AR, Webber RJ, Chang JK, Bensch KG (1984) Growth-hormone-releasing factor immunoreactivity in human endocrine tumors. Am J Pathol 117:167–170
Sanno N, Teramoto A, Osamura RY, Genka S, Katakami H, Jin L, Lloyd RV, Kovacs K (1997) A growth hormone-releasing hormone-producing pancreatic islet cell tumor metastasized to the pituitary is associated with pituitary somatotroph hyperplasia and acromegaly. J Clin Endocrinol Metab 82:2731–2737
Caplan RH, Koob L, Abellera RM, Pagliara AS, Kovacs K, Randall RV (1978) Cure of acromegaly by operative removal of an islet tumor of the pancreas. Am J Med 64:874–882
Saeger W, Shulte HM, Klöppel G (1986) Morphology of a GHRH producing pancreatic islet cell tumor causing acromegaly. Virchows Arch A Pathol Anat Histopathol 409:547–554
Sano T, Yamasaki R, Saito H, Hirose T, Kudo E, Kameyama K, Hiraishi K, Saito S, Hizawa K (1987) Growth hormone-releasing hormone (GHRH)-secreting pancreatic tumor in a patient with multiple endocrine neoplasia type 1. Am J Surg Pathol 11:810–819
Wilson DM, Ceda GP, Bostwick DG, Webber RJ, Minkoff JR, Pont A, Hintz RL, Bensch KG, Kraemer FB, Rosenfeld RG et al (1984) Acromegaly and Zollinger-Ellison syndrome secondary to an islet cell tumor: characterization and quantification of plasm and tumor human growth hormone-releasing factor. J Clin Endocrinol Metab 59:1002–1005
Berger G, Trouillas J, Bloch B, Sassolas G, Berger F, Partensky C, Chayvialle JA, Brazeau P, Claustrat B, Lesbros F et al (1984) Multihormonal carcinoid tumor of the pancreas. Secreting growth hormone-releasing factor as a cause of acromegaly. Cancer 54:2097–2108
Ezzat S, Ezrin C, Yamashita S, Melmed S (1993) Recurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumor. Cancer 71:66–70
Corbetta S, Seracchi M, Cappiello V, Lania A, Lauri E, Vago L, Beck-Peccoz P, Spada A (2003) Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: identification of one pancreatic ghrelinoma. J Clin Endocrinol Metab 88:3117–3120
Clark ES, Carney JA (1984) Pancreatic islet cell tumor associated with Cushing syndrome. Am J Surg Pathol 8:917–924
Heitz PU, Klöppel G, Polak JM, Staubb JJ (1981) Ectopic hormone production by endocrine tumors: localization of hormones at the cellular level by immunocytochemistry. Cancer 48:2029–2037
Torriani F, Uske A, Temler E, Rey F, Hurlimann J, Delaloye B, Gomez F (1989) Pancreatic insuloma causing Cushing’s syndrome. J Endocrinol Invest 12:313–319
Styne DM, Isaac R, Miller WL (1983) Endocrine, histological, and biochemical studies of adrenocorticotropin-producing islet cell carcinoma of the pancreas in childhood with characterization of proopiomelanocortin. J Clin Endocrinol Metab 57:723–731
Lyons DF, Eisen BR, Clark MR, Pysher TJ, Welsh JD, Kem DC (1984) Concurrent Cushing’s and Zollinger-Ellison syndromes in a patient with islet cell carcinoma. Case report and review of the literature. Am J Med 76:729–733
Corrin B, Gilby ED, Jones NF, Patrik J (1973) Oat cell carcinoma of the pancreas with ectopic ACTH secretion. Cancer 31:1523–1527
Matsen S, Yeo CJ, Hruban RH, Choti MA (2005) Hypercalcemia and pancreatic endocrine neoplasia with elevated PTH-rP: report of two new cases and subject review. J Gastrointest Surg 9:270–279
Arps H, Dietel M, Schulz A, Janzarik H, Klöppel G (1986) Pancreatic endocrine carcinoma with ectopic PTH-production and paraneoplastic hypercalcemia. Virchows Arch A Pathol Anat Histopathol 408:497–503
Ratcliffe WA, Bowden SJ, Dunne FP, Hughes S, Emly JF, Baker JT, Pye JK, Williams CP (1994) Expression and processing of parathyroid hormone related protein in a pancreatic endocrine cell tumour associated with hypercalcemia. Clin Endocrinol 40:679–686
Tarver DS, Birch SJ (1992) Case report: life-threating hypercalcemia secondary to pancreatic tumour secreting parathyroid hormone-related protein. Successful control by hepatic arterial embolization. Clin Radiol 46:204–205
Miraliakbari BA, Asa SL, Boudreau SF (1992) Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia. Hum Pathol 23:884–887
Mitlak BH, Hutchinson JS, Kaufman SD, Nussbaum SR (1991) Parathyroid hormone-related peptide mediates hypercalcemia in an islet cell tumor of the pancreas. Horm Metab Res 23:344–346
Rizzoli R, Sappino AP, Bonjour JP (1990) Parathyroid hormone-related protein and hypercalcemia in pancreatic neuroendocrine tumors. Int J Cancer 46:394–398
Rasbach DA, Hammond JM (1985) Pancreatic islet cell carcinoma with hypercalcemia. Primary hyperparathyroidism or humoral hypercalcemia of malignancy. Am J Med 78:337–342
Druker DJ, Asa SL, Henderson J, Goltzman D (1989) The parathyroid hormone-like peptide gene is expressed in the normal and neoplastic human endocrine pancreas. Mol Endocrinol 3:1589–1595
Kim DG, Chejifec G, Prinz RA (1989) Islet cell carcinoma of the pancreas. Am Surg 55:325–332
Thompson GB, van Heerden JA, Grant CS et al (1988) Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery 104:1011–1017
Venkatesh S, Ordonez NG, Ajani J, Schultz PN, Hickey RC, Johnston DA, Samaan NA (1990) Islet cell carcinoma of the pancreas. A study of 98 patients. Cancer 65:354–357
Grimelius L, Hultquist GT, Stenkvist B (1975) Cytological differentiation of asymptomatic pancreatic islet cell tumors in autopsy material. Virchows Arch A Pathol Anat Histopathol 365:275–288
Kimura W, Kuroda A, Morioka Y (1991) Clinical pathology of endocrine tumors of the pancreas: analysis of autopsy cases. Dig Dis Sci 36:933–942
Eckhauser FE, Cheung PS, Vinik AI, Strodel WE, Lloyd RV, Thompson NW (1986) Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery 100:978–988
Evans DB, Skibber JM, Lee JE, Cleary KR, Ajani JA, Gagel RF, Sellin RV, Fenoglio CJ, Merrell RC, Hickey RC (1993) Nonfunctioning islet cell carcinoma of the pancreas. Surgery 114:1175–1182
Henopp T, Anlauf M, Schmitt A, Schlenge R, Zalatnai A, Couvelard A, Ruszniewski P, Schaps KP, Jonkers YMH, Speel EJM, Pellegata NS, Heitz PU, Komminoth P, Perren A, Klöppel G (2009) Glucagons cell adenomatosis: as newly recognized disease of the endocrine pancreas. J Clin Endocrinol Metab 94(1):213–217
Lubensky IA, Pack S, Ault D, Vortmeyer AO, Libutti SK, Choyke PL, Walther MM, Linehan WM, Zhuang Z (1998) Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol 153:223–231
Kent RB, van Heerden JA, Weiland LH (1981) Nonfunctioning islet cell tumors. Ann Surg 193:185–190
Cubilla AL, Hajdu SI (1975) Islet cell carcinoma of the pancreas. Arch Pathol 99:204–207
La Rosa S, Sessa F, Uccella S, Leone BE, Rindi G, Solcia E, Capella C (1997) Histological and immunohistochemical study of calcitonin-cell tumors of the pancreas. Digestion 58(Suppl 2):19
Fleury A, Fléjou JF, Sauvanet A, Molas G, Vissuzaine C, Hammel P, Lévy P, Belghiti J, Bernades P, Ruszniewski P (1998) Calcitonin-secreting tumors of the pancreas: about six cases. Pancreas 16:545–550
Polak JM, Bloom SR, Adrian TE, Heitz P, Bryant MG, Pearse AG (1976) Pancreatic polypeptide in insulinomas, gastrinomas, VIPomas and glucagonomas. Lancet 1:328–330
Adrian TE, Uttenthal LO, Williams SJ, Bloom SR (1986) Secretion of pancreatic polypeptide in patients with pancreatic endocrine tumors. N Engl J Med 315:287–291
Tomita T, Friesen SR, Pollok HG (1991) PP-producing tumors (PPomas). In: Dayal Y (ed) Endocrine tumors of the gut and pancreas. CRC, Boca Raton, pp 279–304
O’Connor TP, Wade TP, Sunwoo YC, Reimers HJ, Palmer DC, Silverberg AB, Johnson FE (1992) Small cell undifferentiated carcinoma of the pancreas. Report of a patient with tumor marker studies. Cancer 70:1514–1519
Reyes CV, Wang T (1981) Undifferentiated small cell carcinoma of the pancreas: report of five cases. Cancer 47:2500–2502
Sessa F, Bonato M, Frigerio B, Capella C, Solcia E, Prat M, Bara J, Samloff IM (1990) Ductal cancers of the pancreas frequently express markers of gastrointestinal epithelial cells. Gastroenterology 98:1655–1665
Kaufmann O, Dietel M (2000) Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology 36:415–420
Klöppel G (2000) Mixed exocrine-endocrine tumors of the pancreas. Semin Diagn Pathol 17:104–108
Üstün MÖ, Tuğyan N, Tunakan M (2000) Coexistence of an endocrine tumour in a serous cystadenoma (microcystic adenoma) of the pancreas, an unusual association. J Clin Pathol 53:800–802
Keel SB, Zukerberg L, Graeme-Cook F, Compton CC (1996) A pancreatic endocrine tumor arising within a serous cystadenoma of the pancreas. Am J Surg Pathol 20:471–475
Leteurtre E, Brami F, Kerr-Conte J, Quandalle P, Lecomte-Houcke M (2000) Mixed ductal-endocrine carcinoma of the pancreas. A case study with mixed ductal-endocrine metastasis double labeled for cytokeratin 19 and synaptophysin. Arch Pathol Lab Med 124:284–286
Klimstra DS, Rosai J, Heffess CS (1994) Mixed acinar-endocrine carcinomas of the pancreas. Am J Surg Pathol 18:765–778
Schron DS, Mendelsohn G (1984) Pancreatic carcinoma with duct, endocrine, and acinar differentiation. A histological, immunocytochemical, and ultrastructural study. Cancer 54:1766–1770
Burgess JR, Greenaway TM, Shepherd JJ (1998) Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1. J Intern Med 243:465–470
Jensen RT (1999) Pancreatic endocrine tumors: recent advances. Ann Oncol 10:S170–S176
Lubensky IA, Debelenko LV, Zhuang Z, Emmert-Buck MR, Dong Q, Chandrasekharappa S, Guru SC, Manickam P, Olufemi SE, Marx SJ, Spiegel AM, Collins FS, Liotta LA (1996) Allelic deletions on chromosome 11q13 in multiple tumors from individual MEN1 patients. Cancer Res 56:5272–5278
Emmert-Buck MR, Lubensky IA, Dong Q, Manickam P, Guru SC, Kester MB, Olufemi SE, Agarwal S, Burns AL, Spiegel AM, Collins FS, Marx SJ, Zhuang Z, Liotta LA, Chandrasekharappa SC, Debelenko LV (1997) Localization of the multiple endocrine neoplasia type 1 (MEN1) gene based on tumor loss of heterozygosity analysis. Cancer Res 57:1855–1858
Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404–407
Guo SS, Sawaicki MP (2001) Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type 1. Mol Endocrinol 15:1653–1664
Calender A, Vercherat C, Gaudray P, Chayvialle JA, GENEM (Groupe d’ Etude des Neoplasies Endocriniennes Multiples) (2001) Deregulation of genetic pathways in neuroendocrine tumors. Ann Oncol 12:S3–S11
Guru SC, Crabtree JS, Brown KD, Dunn KJ, Manickam P, Prasad NB, Wangsa D, Burns AL, Spiegel AM, Marx SJ, Pavan WJ, Collins FS, Chandrasekharappa SC (1999) Isolation, genomic organization, and expression analysis of Men1, the murine homolog of the MEN1 gene. Mamm Genome 10:592–596
Khodaei S, O’Brien KP, Dumanski J, Wong FK, Weber G (1999) Characterization of the MEN1 ortholog in zebrafish. Biochem Biophys Res Commun 264:404–408
Maruyama K, Tsukada T, Honda M, Nara-Ashizawa N, Noguchi K, Cheng J, Ohkura N, Sasaki K, Yamaguchi K (2000) Complementary DNA structure and genomic organization of Drosophila menin. Mol Cell Endocrinol 168:135–140
Agarwal S, Kester MB, Debelenko LV, Heppner C, Emmert-Buck MR, Skarulis MC, Doppman JL, Kim YS, Lubensky IA, Zhuang Z, Green JS, Guru SC, Manickam P, Olufemi SE, Liotta LA, Chandrasekharappa SC, Collins FS, Spiegel AM, Burns AL, Marx SJ (1997) Germline mutations of the MEN1 gene in familial MEN1 and related states. Hum Mol Genet 6:1169–1175
Shimizu S, Tsukada T, Futami H, Ui K, Kameya T, Kawanaka M, Uchiyama S, Aoki A, Yasuda H, Kawano S, Ito Y, Kanbe M, Obara T, Yamaguchi K (1997) Germline mutations of the MEN1 gene in Japanese kindred with multiple endocrine neoplasia type 1. Jpn J Cancer 88:1029–1032
Bassett JHD, Forbes SA, Pannett AAJ, Lloyd SE, Christie PT, Wooding C, Harding B, Besser GM, Edwards CR, Monson JP, Sampson J, Wass JA, Wheeler MH, Thakker RV (1998) Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 62:232–244
Giraud S, Zhang CX, Serova-Sinilnikova O, Wautot V, Salandrem J, Buisson N, Waterlot C, Bauters C, Porchet N, Aubert JP, Emy P, Cadiot G, Delemer B, Chabre O, Niccoli P, Leprat F, Duron F, Emperauger B, Cougard P, Goudet P, Sarfati E, Riou JP, Guichard S, Rodier M, Meyrier A, Caron P, Vantyghem MC, Assayag M, Peix JL, Pugeat M, Rohmer V, Vallotton M, Lenoir G, Gaudray P, Proye C, Conte-Devolx B, Chanson P, Shugart YY, Goldgar D, Murat A, Calender A (1998) Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. Am J Hum Genet 63:455–467
Teh BT, Kytölä S, Farnebo F, Bergman L, Wong FK, Weber G, Hayward N, Larsson C, Skogseid B, Beckers A, Phelan C, Edwards M, Epstein M, Alford F, Hurley D, Grimmond S, Silins G, Walters M, Stewart C, Cardinal J, Khodaei S, Parente F, Tranebjaerg L, Jorde R, Salmela P et al (1998) Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism. J Clin Endocrinol Metab 83:2621–2626
Poncin J, Abs R, Velkeniers B, Bonduelle M, Abramowicz M, Legros JJ, Verloes A, Meurisse M, Van Gaal L, Verellen C, Koulischer L, Beckers A (1999) Mutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type 1 and related diseases. Hum Mutat 13:54–60
Teh BT, McArdle J, Parameswaran V, David R, Larsson C, Shepherd J (1996) Sporadic primary hyperparathyroidism in the setting of multiple endocrine neoplasia type 1. Arch Surg 131:1230–1232
Stock JL, Warth MR, Teh BT, Coderre JA, Overdorf JH, Baumann G, Hintz RL, Hartman ML, Seizinger BR, Larsson C, Aronin N (1997) A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine type 1 locus at chromosome region 11q13. J Clin Endocrinol Metab 82:486–492
Khodaei-O’Brien S, Zablewska B, Fromaget M, Fromaget M, Bylund L, Weber G, Gaudray P (2000) Heterogeneity at the 5′ end of MEN1 transcripts. Biochem Biophys Res Commun 276:508–514
Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, Lorang D, Libutti SK, Chandrasekharappa SC, Marx SJ, Spiegel AM, Collins FS (2001) A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA 98:1118–1123
Guru SC, Goldsmith PK, Burns AL, Marx SJ, Spiegel AM, Collins FS, Chandrasekharappa SC (1998) Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci USA 95:1630–1634
Kaji H, Canaff K, Goltzman D, Hendy GN (1999) Cell cycle regulation of MENIN expression. Cancer Res 59:5097–5101
Scacheri PC, Davis S, Duncan T, Odom DT, Crawford GE, Perkins S, Halawi MJ, Agarwal SK, Marx SJ, Spiegel AM, Meltzer PS, Collins FS (2006) Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet 2:406–418
Scappaticci S, Maraschio P, Del Ciotto N, Fossati GS, Zonta A, Fraccaro M (1991) Chromosome abnormalities in lymphocytes and fibroblasts of subjects with multiple endocrine neoplasia type 1. Cancer Genet Cytogenet 52:85–92
Tomassetti P, Cometa G, Del Vecchio E, Baserga M, Faccioli P, Bosoni D, Paolucci G, Barbara L (1995) Chromosomal instability in multiple endocrine neoplasia type 1. Cytogenetic evaluation with DEB test. Cancer Genet Cytogenet 9:123–126
Sakurai A, Katai M, Itakura Y, Ikeo Y, Hashizume K (1999) Premature centromere division in patients with multiple endocrine neoplasia type 1. Cancer Genet Cytogenet 109:138–140
Hessman O, Skogseid B, Westin G, Akerström G (2001) Multiple allelic deletions and intratumoral genetic heterogeneity in men1 pancreatic tumors. J Clin Endocrinol Metab 86:1355–1361
Richard S, Giraud S, Beround C, Caron J, Penfornis F, Baudin E, Niccoli-Sire P, Murat A, Schlumberger M, Plouin PF, Conte-Devolx B (1998) Von Hippel-Lindau disease: recent genetic progress and patient management. Ann Endocrinol 59:452–458
Neumann HPH, Dinkel E, Brambs H, Wimmer B, Friedburg H, Volk B, Sigmund G, Riegler P, Haag K, Schollmeyer P et al (1991) Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology 101:465–471
Hammel P, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM, Chauveau D, Balian A, Beigelman C, O’Toole D, Bernades P, Ruszniewski P, Richard S (2000) Pancreatic involvement in Von Hippel-Lindau disease. Gastroenterology 119:1087–1095
Hoang MP, Hruban RH, Albores-Saavedra J (2001) Clear cell endocrine pancreatic tumor mimicking renal cell carcinoma: a distinctive neoplasm of von Hippel-Lindau disease. Am J Surg Pathol 125:602–609
Libutti SK, Choyke PL, Bartlett DL, Vargas H, Walther M, Lubensky I, Glenn G, Linehan WM, Alexander HR (1998) Pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease: diagnostic and management recommendations. Surgery 124:1153–1159
Lott ST, Chandler DS, Curley SA, Foster CJ, El-Naggar A, Frazier M, Strong LC, Lovell M, Killary AM (2002) High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumors: evidence for a stepwise mechanism for malignant conversion in VHL tumorigenesis. Cancer Res 62:1952–1955
Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L et al (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317–1320
Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, Oldfield EH, Klausner RD, Linehan WM (1996) Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 93:10589–10594
Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W (1999) The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 13:1822–1833
Pause A, Lee S, Lonergan KM, Klausner RD (1998) The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA 95:993–998
Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, Crossey PA, Webster AR, Affara NA, Ferguson-Smith MA, Brauch H, Glavac D, Neumann HP, Tisherman S, Mulvihill JJ, Gross DJ, Shuin T, Whaley J, Seizinger B, Kley N, Olschwang S, Boisson C, Richard S, Lips CH, Lerman M et al (1996) Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8:348–357
Prowse AH, Webster AR, Richard FM, Richard S, Olschwang S, Resche F, Affara NA, Maher ER (1997) Somatic inactivation of the VHL gene in von Hippel-Lindau disease tumors. Am J Hum Genet 60:765–771
Aubert-Petit G, Baudin E, Cailleux AF, Pellegriti G, Elias D, Travagli JP, Giraud S, Richard S, Schlumberger M (1999) Neuroendocrine tumors and von Hippel-Lindau disease-3 cases. Presse Med 28:1231–1234
Hessman O, Lindberg D, Skogseid B, Carling T, Hellman P, Rastad J, Akerström G, Westin G (1998) Mutation of the multiple endocrine neoplasia type 1 gene in nonfamilian, malignant tumors of the endocrine pancreas. Cancer Res 58:377–379
Shan L, Nakamura Y, Nakamura M, Yokoi T, Tsujimoto M, Arima R, Kameya T, Kakudo K (1998) Somatic mutations of multiple endocrine neoplasia type 1 gene in the sporadic endocrine tumors. Lab Invest 78:471–475
Moore PS, Missiaglia E, Antonello D, Zamò A, Zamboni G, Corleto V, Falconi M, Scarpa A (2001) Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL. Genes Chromosomes Cancer 32:177–181
Zhuang Z, Vortmeyer AO, Pack S, Huang S, Pham TA, Wang C, Park WS, Agarwal SK, Debelenko LV, Kester M, Guru SC, Manickam P, Olufemi SE, Yu F, Heppner C, Crabtree JS, Skarulis MC, Venzon DJ, Emmert-Buck MR, Spiegel AM, Chandrasekharappa SC, Collins FS, Burns AL, Marx SJ, Lubensky IA et al (1997) Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 57:4682–4686
Debelenko LV, Zhuang Z, Emmert-Buck MR, Chandrasekharappa SC, Manickam P, Guru SC, Marx SJ, Skarulis MC, Spiegel AM, Collins FS, Jensen RT, Liotta LA, Lubensky IA (1997) Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res 57:2238–2243
Cupisti K, Hoppner W, Dotzenrath C, Simon D, Berndt I, Röher HD, Goretzki PE (2000) Lack of Men1 gene mutations in 27 sporadic insulinomas. Eur J Clin Invest 30:325–329
Gortz B, Roth J, Krahenmann A, de Krijger RR, Muletta-Feurer S, Rütimann K, Saremaslani P, Speel EJ, Heitz PU, Komminoth P (1999) Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol 154:429–436
Wang EH, Ebrahimi SA, Wu AY, Kashefi C, Passaro E Jr, Sawicki MP (1998) Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res 58:4417–4420
Mailman MD, Muscarella P, Schirmer WJ, Ellison EC, O’Dorisio TM, Prior TW (1999) Identification of MEN1 mutations in sporadic enteropancreatic neuroendocrine tumors by analysis of paraffin-embedded tissue. Clin Chem 45:29–34
Rigaud G, Missiaglia E, Moore PS, Zamboni G, Falconi M, Talamini G, Pesci A, Baron A, Lissandrini D, Rindi G, Grigolato P, Pederzoli P, Scarpa A (2001) High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res 61:285–292
Chung DC, Smith AP, Louis DN, Graeme-Cook F, Warshaw AL, Arnold A (1997) A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J Clin Invest 100:404–410
Nikiforova MN, Nikiforov YE, Biddinger P, Gnepp DR, Grosembacher LA, Wajchenberg BL, Fagin JA, Cohen RM (1999) Frequent loss of heterozygosity at chromosome 3p14.2–3p21 in human pancreatic islet cell tumors. Clin Endocrinol 51:27–33
Barghorn A, Komminoth P, Bachmann D, Rütimann K, Saremaslanim P, Muletta-Feurer S, Perren A, Roth J, Heitz PU, Speel EJ (2001) Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumors and is associated with metastatic progression. J Pathol 194:451–458
Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN (1994) K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 54:1556–1560
Beghelli S, Pelosi G, Zamboni G, Falconi M, Iacono C, Bordi C, Scarpa A (1998) Pancreatic endocrine tumors: evidence for a tumor suppressor pathogenesis and for a tumor suppressor gene on chromosome 17p. J Pathol 186:41–50
Lohmann DR, Funk A, Niedermeyer HP, Häupel S, Höfler H (1993) Identification of p53 gene mutations in gastrointestinal and pancreatic carcinoids by nonradioisotopic SSCA. Virchows Arch B Cell Pathol Incl Mol Pathol 64:293–296
Bartsch D, Hahn SA, Danichevski KD, Ramaswamy A, Bastian D, Galehdari H, Barth P, Schmiegel W, Simon B, Rothmund M (1999) Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene 18:2367–2371
Hessman O, Lindberg D, Einarsson A, Lillhager P, Carling T, Grimelius L, Eriksson B, Akerström G, Westin G, Skogseid B (1999) Genetic alterations on 3p, 11q13 and 18q in nonfamilian and MEN1-association pancreatic endocrine tumors. Genes Chromosomes Cancer 26:258–264
Perren A, Saremaslani P, Schmid S, Bonvin C, Locher T, Roth J, Heitz PU, Komminoth P (2003) DPC4/Smad4: no mutations, rare allelic imbalances, and retained protein expression in pancreatic endocrine tumors. Diagn Mol Pathol 12:181–186
Muscarella P, Melvin WS, Fisher WE, Foor J, Ellison EC, Herman JG, Schirmer WJ, Hitchcock CL, DeYoung BR, Weghorst CM (1998) Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Res 58:237–240
Lubomierski N, Kersting M, Bert T, Muench K, Wulbrand U, Schuermann M, Bartsch D, Simon B (2001) Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors. Cancer Res 61:5905–5910
House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, Cameron JL, Hruban RH, Maitra A, Yeo CJ (2003) Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg 238:423–431
Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR, Rashid A (2003) CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 22:924–934
Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401–406
Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B (2007) Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13:2986–2991
Chung DC, Smith AP, Louis DN, Graeme-Cook F, Warshaw AL, Arnold A (1997) Analysis of the retinoblastoma tumor suppressor gene in pancreatic endocrine tumors. Clin Endocrinol 47:523–528
Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, Heitz PU, Eng C (2000) Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 157:1097–1103
Pearce SHS, Trump D, Wooding C, Sheppard MN, Clayton RN, Thakker RV (1996) Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumors. Clin Endocrinol 45:195–200
Roncalli M, Coggi G (1993) Oncogenes and neuroendocrine tumors. In: Polak JM (ed) Diagnostic histopathology of neuroendocrine tumors. Churchill Livingstone, London, pp 41–66
Speel EJM, Richter J, Moch H, Egenter C, Saremaslani P, Rütimann K, Zhao J, Barghorn A, Roth J, Heitz PU, Komminoth P (1999) Genetic differences in endocrine pancreatic tumor subtype detect by comparative genomic hybridization. Am J Pathol 155:1787–1794
Zhao J, Moch H, Scheidweiler F, Baer A, Schäffer AA, Speel EJ, Roth J, Heitz PU, Komminoth P (2001) Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosome Cancer 32:364–372
Tönnies H, Toliar MR, Ramel C, Toliat MR, Ramel C, Pape UF, Neitzel H, Berger W, Wiedenmann B (2001) Analysis of sporadic neuroendocrine tumors of the enteropancreatic system by comparative genomic hybridisation. Gut 48:536–541
Stumpf E, Aalto Y, Höög A, Kjellman M, Otonkoski T, Knuutila S, Andersson LC (2000) Chromosomal alterations in human pancreatic endocrine tumors. Genes Chromosomes Cancer 29:83–87
Jonkers YM, Claessen SM, Veltman JA, Geurts van Kessel A, Dinjens WN, Skogseid B, Ramaekers FC, Speel EJ (2006) Molecular parameters associated with insulinoma progression: chromosomal instability versus p53 and CK19 status. Cytogenet Genome Res 115:289–297
Ebrahimi SA, Wang EH, Wu A, Schreck RR, Passaro E Jr, Sawicki MP (1999) Deletion of chromosome 1 predicts prognosis in pancreatic endocrine tumors. Cancer Res 59:311–315
Pizzi S, D’Adda T, Azzoni C, Rindi G, Grigolato P, Pasquali C, Corleto VD, Delle Fave G, Bordi C (2002) Malignancy-associated allelic losses on the X-chromosome in foregut but not midgut endocrine tumors. J Pathol 196:401–407
Barghorn A, Speel EJ, Farspour B, Saremaslani P, Schmid S, Perren A, Roth J, Heitz PU, Komminoth P (2001) Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am J Pathol 158:1903–1911
Speel EJ, Scheidweiler AF, Zhao J, Matter C, Saremaslani P, Roth J, Heitz PU, Komminoth P (2001) Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors. Gain of 9q34 is an early event in insulinomas. Cancer Res 61:5186–5192
Jonkers YM, Claessen SM, Feuth T, van Kessel AG, Ramaekers FC, Veltman JA, Speel EJ (2006) Novel candidate tumour suppressor gene loci on chromosomes 11q23-24 and 22q13 involved in human insulinoma tumourigenesis. J Pathol 210:450–458
Barghorn A, Komminoth P, Bachmann D, Rütimann K, Saremaslani P, Muletta-Feurer S, Perren A, Roth J, Heitz PU, Speel EJ (2001) Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression. J Pathol 194:451–458
Couvelard A, Hu J, Steers G, O’Toole D, Sauvanet A, Belghiti J, Bedossa P, Gatter K, Ruszniewski P, Pezzella F (2006) Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors. Gastroenterology 131:1597–1610
Hansel DE, Rahman A, House M, Ashfaq R, Berg K, Yeo CJ, Maitra A (2004) Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clin Cancer Res 10:6152–6158
Maitra A, Hansel DE, Argani P, Ashfaq R, Rahman A, Naji A, Deng S, Geradts J, Hawthorne L, House MG, Yeo CJ (2003) Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin Cancer Res 9:5988–5995
Capurso G, Lattimore S, Crnogorac-Jurcevic T, Panzuto F, Milione M, Bhakta V, Campanini N, Swift SM, Bordi C, Delle Fave G, Lemoine NR (2006) Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer 13:541–558
Driman DK, Kobrin MS, Kudlow JE, Asa SL (1992) Transforming growth factor-α in normal and neoplastic human endocrine tissues. Hum Pathol 23:1360–1365
Srivastava A, Alexander J, Lomakin I, Dayal Y (2001) Immunohistochemical expression of transforming growth factor α and epidermal growth factor receptor in pancreatic endocrine tumors. Hum Pathol 32:1184–1189
Papouchado B, Erickson L, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, Lloyd RV (2005) Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 18:1329–1335
La Rosa S, Uccella S, Capella C, Erba S, Sessa F (2000) Localization of hepatocyte growth factor and its receptor met in endocrine cells and related tumors of the gut and pancreas: an immunohistochemical study. Endocr Pathol 11:315–329
Wulbrand U, Wied M, Zöfel P, Göke B, Arnold R, Fehmann H (1998) Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest 28:1038–1049
Terris B, Scoazec Y, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P, Belghiti J, Fléjou J, Degott C (1998) Expression of vascular endothelial growth factor in digestive neuroendocrine tumors. Histopathology 32:133–138
Chaudhry A, Papanicolaou V, Öberg K, Heldin CH, Funa K (1992) Expression of platelet-derive growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res 52:1006–1012
Höög A, Kjellman M, Nordqvist AC, Höög CM, Juhlin C, Falkmer S, Schalling M, Grimelius L (2001) Insulin-like growth factor-II in endocrine pancreatic endocrine tumours. APMIS 109:127–140
Fjällskog ML, Hessman O, Eriksson B, Janson ET (2007) Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol 46:741–746
Furukawa M, Raffeld M, Mateo C, Sakamoto A, Moody TW, Ito T, Venzon DJ, Serrano J, Jensen RT (2005) Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clin Cancer Res 11:3233–3242
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Rosa, S.L., Furlan, D., Sessa, F., Capella, C. (2010). The Endocrine Pancreas. In: Lloyd, R. (eds) Endocrine Pathology:. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1069-1_17
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1069-1_17
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1068-4
Online ISBN: 978-1-4419-1069-1
eBook Packages: MedicineMedicine (R0)